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A yellow fever (YFV) 17D virus variant, which causes persistent infection of mouse neuroblastoma cells associated with defective cell
penetration and small plaque size, yielded plaque-revertant viruses from cells transfected with viral transcripts encoding the adaptive
mutation (Gly360 in the E protein). Reconstruction of a plaque-purified revertant which contained Gly360 and additional substitutions (Asn for
Lys303 and Val for Ala261) yielded a virus whose infectious center size, growth efficiency, and cell penetration rate similar to the parental
YF5.2iv virus, whereas viruses with Asn303 or Val261 alone with Gly360 yielded either a small-plaque virus or a parental revertant. These data
indicate that the YFV E protein is subject to suppression of mutations in domain III that are deleterious for viral entry and spread by a second-
site mutation in domain II. Position 261 lies within the hydrophobic ligand-binding pocket at the domain I–II interface, a site believed to be
involved in the hinge-like conformational change of domain II during activation of membrane fusion-activity. Results of this study provide
genetic data consistent with findings on flavivirus structure and implicate domain III in functions beyond simply cell surface attachment.
D 2004 Published by Elsevier Inc.Keywords: Yellow fever 17D virus; Cell penetration; E proteinIntroduction
Flaviviruses are small, enveloped positive-sense RNA
viruses containing a single genomic segment of approxi-
mately 11 kb, which encodes a long open reading frame
that produces three structural proteins C (capsid), prM
(precursor to membrane protein), and E (envelope), and at
least seven nonstructural proteins (Rice, 1996). Flavivirus
infections involve initial attachment of virus to host cells
through receptors that have yet to be definitively identified,
and in some cases proteoglycans are involved in early
virus–cell interactions (Anderson, 2003). The viral enve-
lope protein governs the attachment of flaviviruses to
specific receptors which then participate in receptor-
mediated endocytosis and delivery of the virus to an endo-
somal compartment. Low pH-induced conformational
changes render the E protein competent for fusion with
host membranes resulting in release of the RNA genome0042-6822/$ - see front matter D 2004 Published by Elsevier Inc.
doi:10.1016/j.virol.2004.06.015
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E-mail address: chambetj@slu.edu (T.J. Chambers).into the cytoplasm (Heinz and Allison, 2000). Based on the
structure of the soluble fragment of the tick-borne enceph-
alitis (TBE) virus E protein (Rey et al., 1995), domain III
has been implicated in binding to cellular receptors (Bhard-
waj et al., 2001; Crill and Roehrig, 2001; Mandl et al.,
2000). Consequently, some of the virulence determinants
that affect the pathogenesis of flaviviruses in animal models
have been mapped to the lateral edge of this domain (Rey et
al., 1995), and these act presumably through effects on
virus attachment, post-receptor-binding events associated
with virus entry, or both.
Yellow fever (YFV) virus is the prototype member of the
genus Flavivirus within the Flaviviridae (Rice, 1996). In a
previous study, we characterized the properties of a YF 17D
variant associated with persistent infection of a mouse
neuroblastoma cell line (Vlaycheva and Chambers, 2002).
This variant (NB15a) exhibited a lower efficiency of infec-
tion, impaired growth kinetics, reduced cell penetration, and
poor cell-to-cell spread in different cell lines compared to
parental virus (YF5.2iv, produced from YF17D infectious
clone). A single nucleotide substitution encoding a glycine
residue instead of aspartic acid at position 360 in domain III
of the E protein was responsible for the cell culture properties
L. Vlaycheva et al. / Virology 327 (2004) 41–4942of this variant. Although the NB15a virus exhibited a stable
plaque phenotype, YF5.2iv virus engineered to encode this
neuroblastoma-adaptive mutation (Gly360) yielded frequent
plaque-revertant viruses after RNA transfection of Vero cells.
To determine if this reversion phenomenon involved novel
mutations in the structural protein region that might give
insight into functionally important interactions among the
domains of the E protein and its association with prM, we
isolated and characterized a set of plaque-revertant viruses
which were found to harbor second-site mutations. The
mutations were evaluated for effects on plaque size and other
cell culture properties which differentiate the neuroblastoma-
adapted NB15a virus from the parental virus.Results
Isolation and characterization of revertant viruses
Transfection of Vero cells with RNA transcripts from
YF5.2iv virus containing the substitution of glycine for
aspartic acid at amino acid residue 360 of the E protein
yields a very small-plaque virus, similar to the original
NB15a variant (Vlaycheva and Chambers, 2002). However,
these transfections also yield virus progeny with heteroge-
neous plaque sizes ranging from small to parental (data not
shown). To determine if any suppressor mutations were
responsible for this plaque-revertant phenomenon, a total of
four intermediate- and large-plaque revertants were plaque-
purified and their prM-E regions sequenced (Table 1). A
total of nine PCR clones of the two large-plaque viruses
(four for L6 and five for L7), and six PCR clones of the two
intermediate-plaque viruses (two for M2, and four for M8)
were analyzed. None of the plaque revertants contained a
reversion of glycine to aspartic acid at position 360. The
large-plaque (L) revertants consistently contained substitu-Table 1
Mapping of revertant mutations
Clone prM Envelope
YF5.2iv V44 A261K303D360T453
NB15a V44 A261K303G360T453
L6.1 V44 V261N303G360I453
L6.2 V44 V261N303G360T453
L6.3 V44 A261K303G360T453
L6.4 V44 A261K303G360T453
L7.1 V44 A261E303G360T453
L7.2 V44 A261E303G360T453
L7.3 V44 A261E303G360T453
L7.4 V44 A261N303G360T453
L7.5 V44 A261N303G360T453
M2.1 G44 A261K303G360T453
M2.2 G44 A261K303G360T453
M8.1 V44 A261K303G360T453
M8.2 V44 A261K303G360T453
M8.3 V44 A261K303G360T453
M8.4 V44 A261K303G360T453tions at position 303 in the E protein (seven of nine clones),
where a lysine residue was replaced with glutamic acid
(three clones) or asparagine (four clones). Two clones of
large-plaque revertants (L6.1 and L6.2) also showed an
additional substitution of valine for alanine at position 261
of the E protein. Two additional large plaque clones (L6.3
and L6.4) contained no second-site mutations in the struc-
tural region. Among the intermediate-size (M) revertants, a
substitution at residue 44 in the prM region appeared in two
of six clones (M2.1 and M2.2). The other clones from a
second revertant did not contain any mutations in the prM-E
region. Some of these large- and medium-size plaque-
revertant viruses may have contained additional mutations
outside of the prM-E region that are involved in the
revertant phenotype; however, we did not attempt to identify
any such mutations in the present study.
Engineering of revertant viruses
To evaluate the role of the amino acid substitutions
identified in Table 1 in the plaque reversion process of their
respective viruses, a series of viruses containing these
various substitutions either together with the original G360
mutation or with the parental YF5.2iv sequence were
constructed and their viability and plaque sizes determined
(Table 2). Viruses engineered to contain either asparagine or
glutamic acid at position 303 with the parental aspartic acid
at position 360 exhibited small plaque sizes. Viruses engi-
neered to contain either asparagine or glutamic acid at
position 303 together with the glycine substitution at
position 360 also exhibited small-plaque sizes, similar to
that of the NB15a virus. However, virus engineered to
contain the substitutions of asparagine or glutamic acid at
position 303 as well as the substitution of valine for alanine
at position 261, together with the original G360 mutation,
exhibited partial restoration of the parental plaque size (Fig.
1). The transfection harvest of this virus was very hetero-
geneous; however, plaque purification of one of the largest
plaque isolates in this population yielded a virus whose
plaque size was very nearly the same as parental YF5.2iv
(not shown). This isolate (V261N303G360) was used for
further characterization.
Because the presence of valine at position 261 was
associated with reversion of plaque size, the YFV molec-
ular clone was also engineered to encode this substitution
either alone or together with glycine at position 360 to
determine if valine was necessary and sufficient for the
reversion. In two experiments with these two constructs,
no viruses were recovered after transfection. Transfection
harvests from a third experiment for each of these con-
structs yielded viruses with parental plaque sizes; however,
nucleotide sequencing revealed reversions to the parental
YF5.2iv sequence at positions 261 and 360 in both cases.
A virus was also recovered in which valine at 261 was
engineered together with asparagine at 303; however, this
virus exhibited a small plaque size. These data indicate
Fig. 1. Plaque morphology of parental YF5.2iv virus, the G360 (NB15a)
virus, and the engineered pseudo-revertant G360V261N303. Plaque assays
were stained with crystal violet after incubation of the infected monolayers
for 8 days. For the G360 virus, a plaque-purified stock was used, and for
G360V261N303, a harvest from cells 5 days post-transfection was used.
Table 2
Viruses with engineered mutations
Virus Recovery Plaque size
YF5.2iv + parental
G360 + small
N303 + small
E303 + small
E303G360 + small
N303G360 + small
V261N303G360 + intermediate
V261N303 + small
V261G360  a NA
V261  b NA
a Parental revertant in 1/3 transfection.
b Parental revertant in 1/3 transfection.
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mutation for the YF5.2iv virus either by itself, or in the
context of either a glycine or aspartic acid residue at
position 360. In contrast, valine at position 261 can be
tolerated provided that a substitution of asparagine for
lysine occurs at residue 303, suggesting that the latter
mutation compensates in some way for the deleterious
effects of the valine residue.
Characterization of the Val261Asn303Gly360 virus
The Val261Asn303Gly360 virus recovered from RNA trans-
fection as shown in Table 2 was plaque-purified and sub-
jected to nucleotide sequence analysis, and the presence of
the three substitutions in the E protein was verified. The virus
was then characterized with regard to several cell culture
properties which differentiate the neuroblastoma-adapted
NB15a virus from the parental YF5.2iv virus. To confirm
that the increased plaque size of the Val261Asn303Gly360
virus reflected efficient cell-to-cell spread, infected Vero cell
monolayers were examined using an immunofluorescent
focus assay (Fig. 2). Cells infected at low multiplicity were
serially examined for the size of infectious centers in
comparison to the size generated by the parental YF5.2iv
virus. In this type of assay, viruses with different plaque sizes
can be readily distinguished as early as 2 or 3 days postin-
fection. In particular, the Gly360 virus exhibits a markedly
restricted infectious focus size that does not enlarge much
over a period of 8 days postinfection (Vlaycheva and
Chambers, 2002). The V261N303G360 virus formed fluores-
cent foci at day 3 postinfection that were similar in size to
those of YF5.2iv, consistent with the results of the plaque
assay. However, it displayed a somewhat distinct pattern of
spread, as the edges of the foci were less well defined relative
to those formed by YF5.2iv, which were rounder with
sharper edges.
Cell culture growth
To determine if the plaque-revertant phenotype of the
V261N303G360 virus was associated with growth efficiencythat resembled the parental virus, the kinetics of virus
growth were examined in Vero cells after low multiplicity
of infection. In previous studies, we had observed that the
small-plaque neuroblastoma cell-adapted NB15a virus
exhibited reduced growth efficiency in various cell lines
of different host origin in comparison to parental YF5.2iv
virus (Vlaycheva and Chambers, 2002). The growth
profile of the engineered Val261Asn303Gly360 virus was
very similar to that of the YF5.2iv virus (Fig. 3), with
peak virus titers of approximately 6.5 logs PFU/ml
attained after 3 days of incubation. This suggests that
full reversion of this property had taken place. Further-
more, a homogenous plaque size of the Val261Asn303
Gly360 virus was maintained in all time points tested in
this experiment, suggesting that additional mutations,
which might increase growth efficiency, had not accumu-
lated. However, this possibility was not formally investi-
gated by nucleotide sequencing of viruses from the later
time points. Although these data suggest that there is no
difference between Val261Asn303Gly360 virus and YF5.2iv
virus in growth properties, we also cannot exclude the
possibility that host-restricted differences that might exist
in other cell lines.
Cell penetration
The ability of the Val261Asn303Gly360 virus to penetrate
cells was examined using a penetration assay, based on the
acquisition of low pH-resistance by cell-associated virus as
a function of time (Fig. 4). In this assay, which uses a very
low multiplicity of infection, virus adsorption to the mono-
layer is essentially complete within the initial 10 min of
infection (Vlaycheva and Chambers, 2002), thereby mini-
mizing virus binding efficiency as a factor affecting pene-
tration rate and efficiency. Using this assay, substantial
impairment of penetration efficiency of YF virus for differ-
ent cell lines has been demonstrated by substitution of
glycine for aspartic acid at position 360 of the E protein
and with various other amino acid substitutions at this site
(Vlaycheva and Chambers, 2002, and unpublished data). In
particular, both the NB15a and Gly360 viruses exhibit a
Fig. 2. Fluorescent focus assay. Vero cells were infected with parental or plaque-purified G360V261N303 virus at low M.O.I. Samples were processed for indirect
immunofluorescence at day 3 after infection, as described in Materials and methods. Images were taken at 100 and 40 .
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60 min, compared to 70–90% for the parental YF5.2iv virus
(Vlaycheva and Chambers, 2002). In the current study,
YF5.2iv virus exhibited approximately 30% penetration of
Vero cells at 15 min, 55% at 30 min, and 90% at 60 min
(Fig. 4). The Val261Asn303Gly360 virus exhibited slightly
greater extents of penetration at the same time points;
however, the differences were not significant. These data
suggest that the introduction of the substitutions of valine at
261 and asparagine at 303 suppresses the defect in cellFig. 3. Panel A Comparison of growth in cell culture of the G360V261N303
virus (VNG) with the parental YF5.2iv virus. Monolayers of Vero cells
were infected at a multiplicity of 0.002 in triplicates. Virus was harvested at
different time points after infection, and yields were determined by plaque
assay. Values represent mean F SD, as shown by error bars.penetration associated with a glycine residue at position
360, as seen in the NB15a and G360 viruses.Discussion
In this study, we characterized plaque-revertant viruses
that emerged from cell culture of a small-plaque, neuroblas-Fig. 4. Comparison of cell penetration of parental YF5.2iv and
G360V261N303 (VNG) viruses. Penetration assay was performed using the
plaque-purified engineered virus on Vero cells as described in Materials and
methods. The percentage of penetrated virus was determined as the ratio of
PFUs of acid-resistant virus to that of control virus ( 100) for each virus as
a function of time. Data represent combined results of two independent
experiments where samples for each virus at each time point were done in
duplicate. Error bars represent standard deviations of composite results
from the two experiments.
L. Vlaycheva et al. / Virology 327 (2004) 41–49 45toma cell-adapted YF 17D virus variant (NB15a). Their
plaque sizes ranged from intermediate to parental size,
suggesting that genetic heterogeneity in the E protein region
and perhaps elsewhere in the viral genome was involved in
the reversion process. This was confirmed by nucleotide
sequencing, which revealed mutations at several positions in
the prM-E region of viruses chosen to represent the varia-
tion in plaque size. All plaque revertants had the original
substitution of glycine for aspartic acid at residue 360,
which by itself confers the properties of the neuroblastoma
cell-adapted NB15a virus. Thus, second-site mutations in
the E protein conferred the revertant phenotype. Genetic
engineering of the YF5.2iv molecular clone was used to
identify the mutations responsible for this phenomenon. The
majority of mutations tested yielded small-plaque viruses.
However, one virus, Val261Asn303Gly360, had cell cultureFig. 5. Representation of the YF17D E protein based on the TBE virus structure an
Panel A shows the YFV E protein domain III, with the region containing residue 30
Potential hydrogen bond interactions between residues 303 and 380, through side-c
of 303, are shown by dotted lines. Panel B shows predicted effects of substituti
hydrogen bond interactions, and hydrogen bond between the carbonyl oxygen ofproperties that resembled the parental YF5.2iv virus, indi-
cating that its mutations compensated for the deleterious
effect of glycine at position 360. Although substitutions at
both positions 261 and 303 were required to enable the
pseudo-reversion, position 261 is the critical determinant,
since asparagine at position 303 with glycine at 360 yielded
only a small-plaque virus. Rather, asparagine at 303 appears
to counteract the otherwise lethal effects of the valine
substitution.
Second-site substitutions involving either lysine or as-
paragine at residue 303 were frequent among plaque-rever-
tants, suggesting a selection for these substitutions in viruses
harboring glycine at residue 360. Position 303 lies within a
loop connecting the Ax and Ah strands of the Ax-Cx-Dx h-
sheet located on the upper lateral solvent-exposed surface of
domain III of the E protein (Rey et al., 1995) (Fig. 5A).d localization of the mutations in the pseudo-revertant V261N303G360 virus.
3 depicted. Only side chains for residues 303 and 380 are shown for clarity.
hain nitrogens and through side-chain nitrogen of 380 and backbone oxygen
on with asparagine at position 303. The arginine at 380 maintains similar
asparagine and arginine at 380 replaces that contributed by lysine 303.
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at position 380 to form a charge cluster that might be
involved in cell-surface binding or conformational changes
in domain III that occur during membrane fusion (Modis et
al., 2003, 2004). This region is conserved in tick-borne and
most of the mosquito-borne flaviviruses, and several studies
have shown that substitutions at position 303 alter their
phenotypic properties. For example, a lysine to asparagine
substitution in the YF 17D E protein was associated with
fatal vaccine-associated encephalitis (Jennings et al., 1994).
Residue 303 is adjacent to an antibody epitope which
distinguishes wild type from vaccine strains of YFV and is
associated with neutralization-escape mutations (phenylala-
nine 305 to valine or serine) (Ryman et al., 1998) that
modulate neurovirulence properties conferred by a determi-
nant in a distal region of domain II (residue 240). In
addition, mutagenesis studies of the corresponding region
of the TBE virus E protein demonstrated that lysine 311
(equivalent to YFV lysine 303 in the E protein alignment)
modulates the effects of adjacent substitutions on virus
growth efficiency, plaque size, and mouse neuroinvasive-
ness (Mandl et al., 2000). This was proposed to result from
disruption of a potential cellular receptor-binding determi-
nant. However, the mechanisms have not been defined, and
recent findings suggest that other functions of domain III
beyond cell attachment may also be involved (see below).
Since the E protein of the neuroblastoma cell-adapted YF
NB15a virus loses a negative charge through substitution of
glycine for aspartic acid at residue 360, the additional
substitution of glutamic acid or asparagine for lysine at
position 303 might affect the properties of this virus in part
by restoration of the net charge of domain III. For instance,
loss of lysine at residue 303 might also contribute to a small-
plaque phenotype by reducing interaction of the E protein
with cell surface glycosaminoglycans (GAGs), as these
substances affect the infectivity of YF and dengue viruses
(Chen et al., 1997; Germi et al., 2002), and loss of GAG
binding correlates directly with reduced plaque size (Lee
and Lobigs, 2000; Mandl et al., 2001). Similar to glutamic
acid at position 303, asparagine is predicted to interact with
arginine at 380 through hydrogen bond formation, without
any obvious change to the local structure surrounding this
residue (Fig. 5B). Although both asparagine and glutamic
acid were tolerated at position 303, neither substitution
resulted in plaque reversion, indicating that charge restora-
tion alone is insufficient to restore the properties of the
parental virus.
Since substitutions at position 303 did not revert the
plaque size of virus containing glycine at position 360,
substitution of valine at residue 261 appears to be a primary
factor in the pseudo-revertant phenomenon. Introduction of
valine at 261 was either lethal or resulted in reversion to the
parental alanine residue, suggesting that valine at this
position causes a functional alteration in the E protein.
Studies on the structure of dengue-2 virus have shown that
the corresponding residue is in the hinge region of domainII, within a conserved hydrophobic pocket (residues 268–
280), which includes the ‘‘k–l loop’’. This loop is impli-
cated in a conformational change of domain II that is
required for the dimer-to-trimer conversion of the E protein
(Modis et al., 2003), and studies have shown that mutations
in the hinge alter the pH threshold for membrane fusion and
affect flavivirus virulence in animal models (Beasley and
Aaskov, 2001; Cecilia and Gould, 1991; Hasegawa et al.,
1992; Hurrelbrink and McMinn, 2001; Lee et al., 1997;
Monath et al., 2002). In particular, substitutions with hy-
drophobic amino acids having smaller side chains are
proposed to lower the pH threshold by allowing tighter
closure of the hinge (Modis et al., 2003). Residue 261 in the
YFV E protein (corresponding to residue 267 of the dengue-
2 E protein) lies at the edge of the k–l loop (Fig. 6).
Modeling of valine at 261 suggests that it occupies a
hydrophobic pocket associated with residues tryptophan at
203, leucine at 258, methionine at 262, and valine at 264,
which form the base of the loop. It is conceivable that
replacement of alanine with the larger valine residue desta-
bilizes closure of the k–l loop, resulting in deleterious
effects on the function of the E protein. Interestingly, a
mutation at position 260 of the FNV E protein was observed
to strongly attenuate mouse neurovirulence in association
with reduced binding of virus to brain membrane receptor
preparations (Ni et al., 2000). Regardless of the individual
effects of substitutions at positions 261 and 303, it remains
unclear how they compensate for the defect caused by a
glycine at position 360, and why the substitution at 303 is
required. A possible explanation is that the valine substitu-
tion at 261 promotes fusion by lowering the pH threshold
and facilitating the hinge-like conformational change of
domain II, but this process may have lethal effects in the
absence of an additional mutation at position 303. In this
regard, the recent report of the post-fusion structure of the
dengue-2 virus E protein describes a major conformational
change in domain III, wherein it folds back over and
contacts the adjacent domain I, as the carboxy terminus
moves towards the fusion loop (Bressanelli et al., 2004;
Modis et al., 2004). Substitution with glutamic acid or
asparagine at residue 303 might restrict this movement of
domain III during the conformational change, and counter-
act a lethal effect of the valine residue at position 261.
Additional studies which examine the effects of mutations at
residues 261 and 303 on cell entry and membrane fusion are
needed to determine the mechanism underlying the pseudo-
reversion and provide insight into the molecular basis for
the function of the E protein during virus entry.Materials and methods
Cells and viruses
Vero cells, originally obtained from Jerry Jennings,
USAMRIID, were grown at 37 jC in alpha minimal essential
Fig. 6. Depiction of domain II of the YF 17D E protein in the region of the k– l loop, with the valine substitution at residue 261 inserted. The
corresponding k– l loop for dengue-2 virus (amino acids 268–282) is shown in red for comparison. For clarity, amino acids 194–202 of YFV have been
deleted. The predicted k– l loop of YFV is four amino acids longer than that of dengue-2, consisting of residues 262–280. Valine 261 is predicted to
interact with arginine 263 through hydrogen bonds formed between backbone nitrogens and oxygens of both of these residues, respectively, as shown by
dotted lines.
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and antibiotics [penicillin/streptomycin (Gibco/BRL)].
NB41A3 cells were obtained from the American Type
Culture Collection and grown as previously described
(Vlaycheva and Chambers, 2002). YF5.2iv virus was de-
rived from an infectious clone of the YF 17D virus (Rice et
al., 1989). The NB15a virus was previously obtained by
passaging YF5.2iv in mouse neuroblastoma cells (Vlay-
cheva and Chambers, 2002). The G360 virus, which contains
a single amino acid substitution (glycine for aspartic acid at
residue 360 of the E protein), was engineered using a full-
length YF5.2iv infectious RNA template, as previously
described (Vlaycheva and Chambers, 2002). Titers of all
viruses were determined by plaque assays on Vero cells at
37 jC.
Derivation of revertant viruses
Plaque revertants were isolated from Vero cell cultures
transfected with infectious YFV RNA encoding the sub-
stitution of glycine at amino acid 360 of the E protein.
Plaque assays of the transfection harvests revealed hetero-
geneous plaque sizes involving as much as 10–20% of the
population of the progeny virus. Based on plaque assay of
8 days duration, sizes of plaques were assessed as follows:
large: >5 mm diameter (parental YF5.2iv virus), medium:
2–3 mm, and small: <1 mm. Two of both the medium-size
and large-size plaque revertants were plaque-purified on
Vero cells and amplified on NB41A3 cells before further
characterization.Nucleotide sequencing
Total RNAwas extracted from infected cells using TRIzol
Reagent (Life Technologies) according to the manufacturer’s
protocol. RNA was resuspended in 10 mM Tris–chloride,
pH 7.5, containing 0.1 mM EDTA, aliquoted, and stored at
70 jC. Nucleotide primers were designed to amplify the
region of the YF 17D virus from nucleotides 424 to 2500 by
reverse transcription and PCR (RT-PCR). First-strand cDNA
was synthesized using Superscript II reverse transcriptase
(Gibco/BRL) and approximately 1.5 Ag of total RNA at 46
jC for 1 h, followed by incubation at 70 jC for 10 min.
cDNA products were then subjected to PCR amplification
using Deep Vent DNA polymerase (New England Biolabs)
using the same 3V primer and a 5V primer to produce a PCR
product of approximately 2.0 kb long. PCR was run at 95 jC
for 2 min, followed by 36 cycles of 1 min at 95 jC, 2 min at
50 jC, and 2 min at 72 jC, and then 7 min at 72 jC. PCR
products were isolated from low-melting-temperature aga-
rose gels (BioWhittaker) and purified using Wizard PCR
Preps kits (Promega). Purified PCR products were cloned
into pCR-Blunt II-TOPO using the Zero Blunt-TOPO PCR
cloning kit (Invitrogen), and the ligation products were
transformed into TOP10 E. coli cells. Selected colonies were
grown in small-scale cultures in LB broth plus kanamycin.
DNA was purified from bacterial cells using Wizard Preps
DNA Purification System (Promega). Plasmids were ana-
lyzed by restriction enzyme digestion for presence of YF
17D sequences, and subjected to nucleotide sequencing
using the Beckman cycle sequencing protocol.
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A two-plasmid system for generation of infectious YF
17D virus (Rice et al., 1989) was used to reconstruct YF
virus harboring second-site mutations found in the rever-
tants. RT/PCR-derived clones harboring the mutations from
the plaque-revertant viruses in pZeroBlunt-TOPO were
used for these constructions. To construct pYFM5.2 deriv-
atives containing the second-site mutations by themselves,
NsiI/Sse8387I restriction fragments from the zero-blunt
plasmids were exchanged for the corresponding fragments
from YFM5.2. To construct pYFM5.2 derivatives contain-
ing the second-site mutations together with the G360
mutation, NsiI/Sse8387I restriction fragments from the
zero-blunt plasmids were exchanged for the corresponding
fragments from YFM5.2 containing this mutation. The
transcription templates for the YF genomes were generated
by in vitro ligation using T4 DNA ligase (NEB), of AatII
and NsiI restriction fragments from two plasmids,
pYF5V3VIV and pYFM5.2. Transcription with SP6 RNA
polymerase in the presence of 5V cap analog was done to
produce full-length viral RNA for transfection into cells,
essentially as previously described (Rice et al., 1989).
Approximately 350 ng of RNAs were transfected into Vero
cells in the presence of 20 Ag of Lipofectin (Gibco/BRL),
followed by incubation at 37 jC in alpha MEM plus 5%
FBS. Viruses were harvested from the cell culture at time
of onset of cytopathic effects (typically 5–8 days post-
transfection) and the yields were determined by plaque
assay on Vero cells.
Fluorescent focus assay
Infectious-center assay was performed using fluores-
cence as previously described (Vlaycheva and Chambers,
2002). Confluent monolayers of Vero cells were infected for
1 h at 37 jC with approximately 20 PFU of virus per well.
Virus was removed, and monolayers were overlaid with 1%
agarose (BMA) in alpha-MEM plus 5% FBS, and incubated
at 37 jC. At 3 days postinfection, cells were processed for
immunofluorescence by fixation in 4% paraformaldehyde
and removal of agarose. Cells were permeabilized with
100% cold methanol, incubated with primary antiserum
(anti-YF hyperimmune ascitic fluid (ATCC) diluted 1:500
in PBS plus 1% FBS), washed with PBS, and then
incubated with secondary antibody [affinity-purified fluo-
rescein-conjugated goat anti-rabbit IgG antibody (ICN),
1:50 in PBS plus 1% FBS]. Cells were examined using a
Nikon TE-300 fluorescent microscope equipped with a
standard FITC fluorescence cube and a SPOT camera
(Diagnostic Instruments).
Cell penetration assay
Penetration rate was determined by a previously de-
scribed method (Vlaycheva and Chambers, 2002). Mono-
L. Vlaycheva et al. / V48layers of Vero cells in 60-mm culture plates in quadruplicates
were adsorbed at 37 jC with approximately 50 PFU of virus
per plate. At various intervals up to 60 min, unbound virus
was removed, and replicate samples were treated with acid
glycine buffer (pH 3.0) (0.1 M glycine and 0.1 M sodium
chloride) for 3 min to inactivate uninternalized virus, where-
as a third sample (nonacid-treated control) was washed with
PBS. In previous studies, this treatment was found to
inactivate the majority (>90%) of input viruses (Vlaycheva
and Chambers, 2002). All samples were then washed once
with PBS, overlaid with agarose, and incubated at 37 jC to
allow plaque formation. Percentage of penetrated virus for
each time point was calculated as the ratio of the number of
plaques on the acid-treated cells to the number of plaques on
the nonacid-treated cells for each time point  100.
Molecular modeling
A homology-based model for the YF17D E protein was
derived using the comparative protein modeling server
(Swiss-Model) and the structure of the soluble ectodomain
of the tick-borne encephalitis virus E protein (pdb code
1svb), as described previously (Nickells and Chambers,
2003). The model was used for analysis of the effects of
substitutions at amino acid position 303 using various
rotamer configurations to determine energy parameters
and predicted hydrogen bond formations for the most
favorable conformations of these residues. The region
surrounding residue 261 was modeled using the ‘‘open’’
form of the dengue-2 virus E protein crystallized in the
presence of n-octyl-h-D-glucoside (pdb code 1oke) as the
template. Figures were drawn using the Swiss-Modeller
graphics platform.Acknowledgments
This study was supported by grants from the NIAID (AI-
43512), and CDC (CI-000094) to T.J.C.References
Anderson, R., 2003. Manipulation of cell surface molecules by flaviviruses.
In: Chambers, T.J., Monath, T.P. (Eds.), The Flaviviruses: Structure,
Replication and Evolution. Adv. Virus Res, vol. 59. Elsevier/Academic
Press, London, pp. 230–274.
Beasley, D.W., Aaskov, J.G., 2001. Epitopes on the dengue 1 virus enve-
lope protein recognized by neutralizing IgM monoclonal antibodies.
Virology 279, 447–458.
Bhardwaj, S., Holbrook, M., Shope, R.E., Barrett, A.D.T., Watowich, S.J.,
2001. Biophysical characterization and vector-specific antagonist ac-
tivity of domain III of the tick-borne flavivirus envelope protein.
J. Virol. 75, 4002–4007.
Bressanelli, S., Stiasny, K., Allison, S.L., Stura, E.A., Duquerroy, S., Les-
car, J., Heinz, F.X., Rey, F.A., 2004. Structure of a flavivirus envelope
glycoprotein in its low-pH-induced membrane fusion conformation.
EMBO J. 23, 728–738 (Electronic publication 2004 Feb 12).
L. Vlaycheva et al. / Virology 327 (2004) 41–49 49Cecilia, D., Gould, E.A., 1991. Nucleotide changes responsible for loss of
neuroinvasiveness in Japanese encephalitis virus neutralization-resistant
mutants. Virology 181, 70–77.
Chen, Y., Maguire, T., Hileman, R.E., Fromm, J.R., Esko, J.D., Linhardt,
R.J., Marks, R.E., 1997. Dengue virus infectivity depends on envelope
protein binding to target cell heparan sulfate. Nat. Med. 3, 866–871.
Crill, W.D., Roehrig, J.T., 2001. Monoclonal antibodies that bind to domain
III of dengue virus E glycoprotein are the most efficient blockers of
virus adsorption to Vero cells. J. Virol. 75, 7769–7773.
Germi, R., Crance, J.M., Garin, D., Guimet, J., Lortat-Jacob, H., Rui-
grok, R.W., Zarski, J.P., Drouet, E., 2002. Heparan sulfate-mediated
binding of infectious dengue virus type 2 and yellow fever virus.
Virology 292, 162–168.
Hasegawa, H., Yoshida, M., Shiosaka, T., Fijita, S., Kobayashi, Y., 1992.
Mutations in the envelope protein of Japanese encephalitis virus affect
entry into cultured cells and virulence in mice. Virology 191, 158–165.
Heinz, F.X., Allison, S.A., 2000. Structures and mechanisms in flavivirus
fusion. Adv. Virus Res. 55, 231–269.
Hurrelbrink, R.J., McMinn, P.C., 2001. Attenuation of Murray Valley
encephalitis virus by site-directed mutagenesis of the hinge and puta-
tive receptor-binding regions of the envelope protein. J. Virol. 75,
7692–7702.
Jennings, A.D., Gibson, C.A., Miller, B.R., Mathews, J.H., Mitchell, C.J.,
Roehrig, J.T., Wood, D.J., Taffs, F., Sil, B.K., Whitby, S.N., et al., 1994.
Analysis of a yellow fever virus isolated from a fatal case of vaccine-
associated human encephalitis. J. Infect. Dis. 169, 512–518.
Lee, E., Lobigs, M., 2000. Substitutions at the putative receptor-binding
site of an encephalitis flavivirus alter virulence and host cell tropism
and reveal a role for glycosaminoglycan in entry. J. Virol. 74,
8867–8875.
Lee, E., Weir, R.C., Dalgarno, L., 1997. Changes in the dengue virus
major envelope protein on passaging and their localization on the
three-dimensional structure of the protein. Virology 232, 281–290.
Mandl, C., Allison, S., Holzmann, H., Meixner, T., Heinz, F.X., 2000.
Attenuation of tick-borne encephalitis virus by structure-based site-
specific mutagenesis of a putative flavivirus receptor-binding site.
J. Virol. 74, 9601–9609.
Mandl, C.W., Kroschewski, H., Allison, S.L., Kofler, R., Holzmann, H.,
Meixner, T., Heinz, F.X., 2001. Adaptation of tick-borne encephalitisvirus to BHK-21 cells results in the formation of multiple heparan
sulfate binding sites in the envelope protein and attenuation in vitro.
J. Virol. 75, 5627–5637.
Modis, Y., Ogata, S., Clements, D., Harrison, S.C., 2003. A ligand-binding
pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci.
U.S.A. 100, 6986–6991 (Electronic publication 2003 May 20).
Modis, Y., Ogata, S., Clements, D., Harrison, S.C., 2004. Structure of the
dengue virus envelope protein after membrane fusion. Nature 427,
313–319.
Monath, T.P., Arroyo, J., Levenbook, I., Zhang, Z.X., Catalan, J., Drap-
er, K., Guirakhoo, F., 2002. Single mutation in the flavivirus enve-
lope protein hinge region increases neurovirulence for mice and
monkeys but decreases viscerotropism for monkeys: relevance to
development and safety testing of live, attenuated vaccines. J. Virol.
76, 1932–1943.
Ni, H., Ryman, K.D., Wang, H., Saeed, M.F., Hull, R., Wood, D.,
Minor, P.D., Watowich, S.J., Barrett, A.D.T., 2000. Interaction of
yellow fever virus French neurotropic vaccine strain with monkey
brain: characterization of monkey brain membrane receptor escape
variants. J. Virol. 74, 2903–2906.
Nickells, M., Chambers, T.J., 2003. Neuroadapted yellow fever 17D: deter-
minants in the envelope (E) protein govern neuroinvasiveness for SCID
mice. J. Virol. 77, 12232–12242.
Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C., 1995. The
envelope glycoprotein from tick-borne encephalitis virus at 2 A reso-
lution. Nature 375, 291–298.
Rice, C.M., 1996. Flaviviridae: the viruses and their replication. In:
Fields, B.N., Knipe, D.M., Howley, P.M., et al., (Eds.), Fields Virol-
ogy, 3rd ed. Lippincott-Raven, Philadelphia, PA, pp. 931–960.
Rice, C.M., Grakoui, A., Galler, R., Chambers, T.J., 1989. Transcription of
infectious yellow fever RNA from full-length cDNA templates pro-
duced by in vitro ligation. New Biol. 1, 85–96.
Ryman, K.D., Ledger, T.N., Campbell, G.A., Watowich, S.J., Barrett,
A.D.T., 1998. Mutation in a 17D-204 vaccine substrain-specific enve-
lope protein epitope alters the pathogenesis of yellow fever virus in
mice. Virology 244, 59–65.
Vlaycheva, L., Chambers, T.J., 2002. Neuroblastoma cell-adapted yellow
fever 17D: characterization of a viral variant associated with persistent
infection and decreased virus spread. J. Virol. 76, 6172–6184.
